


A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Curriculum Vitae

Personal Information	
Title (i.e. Pf., Dr., etc.)	Professor
Name (First name Middle name Last name)	Chun-Ying Wu
Degree (i.e. MD, Msc, PhD, etc.)	MD, PhD, MPH, LL.M, LL.B
Country	Taiwan
Affiliation	National Yang Ming Chiao Tung University
	
Educational Background	
Ph.D.	National Taiwan University, Taipei, Taiwan, 2007
LL.M.	Harvard Law School, Cambridge, Massachusetts, USA, 2003
LL.B.	Tunghai University, Taichung, Taiwan, 2000
MPH	Harvard School of Public Health, Cambridge, Massachusetts, USA, 1993
M.D.	National Taiwan University, Taipei, Taiwan, 1991
Professional Experience	
Associate Dean, College of Medicine, National Yang Ming Chiao Tung University Convenor, Public Health & Social Medicine Division, Ministry of Science and Technology Chief, Institute Biomedical Informatics, National Yang Ming Chiao Tung University Chief, Division of Translational Research, Taipei Veterans General Hospital Joint Appointment Researcher, National Institute of Cancer Research Editor-in-Chief, Advances in Digestive Medicine (Official journal of GEST, DEST, & TASL) Associate Editor-in-Chief, Journal of Gastroenterology and Hepatology Editorial Board, Gut Medical Model Award, 2018, Taiwan Medical Association National Innovation Award, 2016, Taiwan Institute for Biotechnology & Medicine Industry Outstanding Research Award, 2015, Taiwan Ministry of Science and Technology Emerging Leadership Lectureship Award, 2015, Asian Pacific Association of Gastroenterology	

A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Professional Organizations

President, Taiwan Microbiome Consortium
Executive Director, Society of Law and Medicine, Taiwan
Director, Taiwan Evidence-based Medicine Society
Director, Taiwan Liver Cancer Association

Main Scientific Publications

1. **Wu CY**, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma following liver resection. **JAMA** 2012 Nov 12; 308(18): 1906-13 (SCI, IF **56.272**).
2. **Wu CY**, Wu MS, Kuo KN, Chen YJ, Wang CB, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in *Helicobacter pylori*-infected patients. **J Clin Oncol** 2010 Jun; 28(18): 2952-7. (SCI, IF **44.544**)
3. Hsu YC, Yip TCF, Ho HJ, Wong VWS, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GLH, **Wu CY***. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. **J Hepatol** 2018 Aug; 69(2): 278-85 (SCI, IF **25.083**).
4. Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, **Wu CY***. First-line *Helicobacter pylori* eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. **Gut** 2018 Jan; 67(1): 20-7 (SCI, IF **23.059**).
5. **Wu CY**, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. **Gut** 2016 Apr; 65(4): 693-701 (SCI, IF **23.059**).
6. Yeo YH, Ho HJ, Yang HI..., **Wu CY***, Nguyen MH. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. **Gastroenterology** 2019 Feb; 156(3): 635-46 (SCI, IF **22.682**).
7. **Wu CY**, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogues therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. **Gastroenterology** 2014 Jul; 147(1): 143-51.e5 (SCI, IF **22.682**).
8. **Wu CY**, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT. Histamine-2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. **Gastroenterology** 2010 Oct; 139(4): 1165-71 (SCI, IF **22.682**).
9. **Wu CY**, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early *Helicobacter pylori* eradication decreases risk of gastric cancer in patients with peptic ulcer disease. **Gastroenterology** 2009 Nov; 137(5):1641-8 (SCI, IF **22.682**).
10. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, **Wu CY***. Association of daily aspirin therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B. **JAMA Intern Med** 2019 May 1; 179(5): 633-40 (SCI, IF **21.873**, 8/167).

IMKASID 2022

COMMEMORATING THE 20th ANNIVERSARY OF KASID

THE 5th INTERNATIONAL MEETING ON INTESTINAL DISEASES IN CONJUNCTION WITH
THE ANNUAL CONGRESS OF THE KOREAN ASSOCIATION FOR THE STUDY OF INTESTINAL DISEASES

MAY 12^{THU} - 14^{SAT}, 2022 / BEXCO, Busan **IN PERSON & VIRTUAL EVENT** ▶▶

A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

